Delivery Order SPE2DB22D7058-SPE2DB26FSUG7
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $5,381.68 to AmerisourceBergen Drug Corp for Amlodipine-Valsartan 10-320 mg tablets (30-count) on October 20, 2025, with completion scheduled for October 21, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 7, 2025, for the supply of Amlodipine-Valsartan 10-160 mg tablets (30-count) valued at $1,819.38. This is a firm fixed-price, non-set-aside contract with a completion date of November 10, 2025, and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,703.95 to AmerisourceBergen Drug Corp for the supply of Amlodipine-Valsartan 10-320 mg tablets (30-count units) on August 22, 2025, with completion targeted for August 25, 2025. The contract employs firm fixed pricing with no set-aside designation, indicating it was competitively awarded. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for...
- The Defense Logistics Agency awarded a delivery order valued at $1,138.04 to AmerisourceBergen Drug Corp for the supply of Amlodipine-Valsartan 10-160 mg tablets (30-count) on June 20, 2025, with an ultimate completion date of June 23, 2025. This competitively awarded, non-set-aside contract employs firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Amlodipine-Valsartan 10-320 mg tablets (30-count supply) with a ceiling value of $1,936.74. This is a firm fixed-price delivery order with no set-aside designation, issued under competitive procedures. The contract is set to conclude on September 8, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Amlodipine-Valsartan 5-160 mg tablets (30-count) under a firm fixed-price contract valued at $1,129.61. The order was competitively awarded without set-aside designation and is scheduled for completion by August 1, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the delivery from its corporate office location. This delivery order represents a...
- The Defense Logistics Agency awarded a firm fixed price delivery order to AmerisourceBergen Drug Corp, valued at $1,812.56, for the supply of Amlodipine-Valsartan 10-160 mg tablets (30-count supply) with an ultimate completion date of August 27, 2025. This non-set-aside contract represents a routine pharmaceutical procurement executed through the company's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through...
- The Defense Logistics Agency awarded a delivery order valued at $1,664.45 to AmerisourceBergen Drug Corp for the supply of Valsartan-HCZ 320-25 mg tablets (90-count) on November 4, 2025, with completion expected by November 5, 2025. This competitively awarded, non-set-aside contract features firm fixed pricing and is being performed in Conshohocken, Pennsylvania, where AmerisourceBergen's corporate office is located. The delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $1,700.58 to AmerisourceBergen Drug Corp for Amlodipine-Valsartan 5-160 mg tablets (30-count) on September 8, 2025, with a completion date of September 9, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and specifies Conshohocken, Pennsylvania as the place of performance. The award represents a child contract under AmerisourceBergen's larger indefinite delivery contract (IDC) with...
- The Defense Logistics Agency has awarded a delivery order valued at $8,336.56 to AmerisourceBergen Drug Corp for the supply of Amlodipine-Valsartan 10-160 mg tablets (30-count packages). This firm fixed-price, non-set-aside contract was awarded on August 25, 2025, with an ultimate completion date of August 26, 2025, and will be performed at the vendor's Corporate Office location in Conshohocken, Pennsylvania. Amlodipine-Valsartan is a combination antihypertensive medication used in the treatment...
- SPE2DB22D7058Indefinite Delivery Contract
- SPE2DB22D7058-SPE2DB26FSUG7Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,547.18 to AmerisourceBergen Drug Corp on November 10, 2025, for the supply of Amlodipine-Valsartan 10-320 mg tablets (30-count). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of November 12, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive $999,999,999.00 global pharmaceutical support vehicle running through December 2026 that enables AmerisourceBergen to supply a broad range of pharmaceuticals and medical supplies to military healthcare programs worldwide. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The company's extensive federal contract portfolio demonstrates consistent capability to fulfill diverse pharmaceutical supply requirements through open competition, including brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. This delivery order for cardiovascular medication represents a routine transaction within the company's established relationship with DLA, supporting the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.5k | 11/10/25 |